BioWorld

Feb. 23, 2010

Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal

Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today) Read More

FDA Raises Endpoint Concerns in Study of Salix Liver Drug

Blocking Backup Pathway Could Prevent Glioblastoma Comeback

New Money Scarce, so ITS Founders Chip in $13.4M

Icahn Makes Move as Genzyme Looks for Good News in 2010

White House Health Bill Adopts 12 Years for FOBs

NIH Stem Cell Definition Change 'Hugely Important'

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 13, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026